《药物经济学与政策：视角、前景和问题》第3版

English | ISBN: 0190623780 | 2018 | 432 pages | PDF | 5 MB

Pharmaceuticals constitute a relatively small share of the total healthcare expenditure in most developed economies, and yet they play a critical role in the ongoing debate over how best to advance, improve, and afford healthcare. Despite this, and perhaps because of this, the industry has had, for many years, an outsized claim to fame and controversy, praise and criticisms, support and condemnation. Unfortunately, many participants in the debate do not fully understand the complexities of the industry and its role in the overall healthcare system.

The analytical tools of economics provide a strong foundation for a better understanding of the dynamics of the pharmaceutical industry, its contribution to health and healthcare, its dual and often conflicting priorities of affordability and innovation, as well as the various private and public policy initiatives directed at the sector. This third edition of a uniquely comprehensive and balanced examination of the industry includes several new chapters on important topics such as the full-fledged generics sector, the arrival of biosimilars or generic biological drugs, the global consolidation of manufacturers, the evolving reimbursement landscape, and the emergence of the world's most populous nations, such as China, India, and Brazil, as both suppliers and consumers of pharmaceutical products. Other chapters have been fully rewritten or extensively updated, covering such important topics as the cost efficiency of research and development, pace of new innovations, economic evaluation and value-based pricing of drugs, and public and private interventions in the industry.

制药业在大多数发达国家的总医疗卫生支出中所占份额相对较小，但其在如何最好推进、改善并负担得起医疗保健方面的辩论中扮演着关键角色。尽管如此，或许正是因为这一点，这个行业多年来一直有着过大的名声和争议，得到赞美和批评，受到支持和谴责。不幸的是，许多参与者在辩论中的理解并未充分认识到该行业及其在整个医疗卫生系统中的作用的复杂性。 经济学的分析工具为更好地理解和把握制药业的动态、其对健康和医疗保健的贡献、其既相互矛盾又经常存在的可负担性和创新优先事项，以及针对该行业的各种私人和公共政策举措提供了一个坚实的基础。本版作为独一无二且全面平衡评估该行业第三版，包括了一些关于重要主题的新章节，如完整仿制药领域的成熟、单克隆抗体或生物仿制药的到来、制造商的全球整合、付款格局的变化趋势，以及中国、印度和巴西等人口最多国家既是药品供应商又是消费者的角色。其他章节也已重新编写或进行了大量更新，涵盖诸如研发成本效率、新创新的速度、药物经济评估和基于价值定价等方面的重要议题，以及行业中的公私干预措施。

---

Download from free file storage

 Download from nitroflare.com  Download from rapidgator.net

---

我要反馈

---

本站不对文件进行储存，仅提供文件链接，请自行下载，本站不对文件内容负责，请自行判断文件是否安全，如发现文件有侵权行为，请联系管理员删除。